Authors
Latest:
Pharma's ESG Equation: Materiality and Strategy are KeyLife sciences executives who are confronted by too many choices in launching their environmental, social, and governance programs can leverage these two foundational tools to hone in on the set of issues, actions, and disclosures they should prioritize to create value.
Latest:
Project Orbis: Implications for Access and Pricing in the UKPost-Brexit, the UK’s MHRA is looking to join Project Orbis, a global program to speed up patient access to innovative cancer treatments. This article looks at the implications of Project Orbis for commercialization in the UK and the key considerations for industry in considering the project as a pathway.
Latest:
Industry Game Changer: RWE Impacts on Drug DevelopmentCOVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.
Latest:
The Power of Virtual Patient Simulation in CMEVPS access for clinicians is critical in today’s healthcare climate
Latest:
Assessing IDMP MaturityHow pharma firms assess their readiness for IDMP (Identification of Medicinal Products) is important for meeting compliance requirements and ensuring they are prepared for the digital product information management future, writes Adnan Jamil.
Latest:
Is Community the Next Frontier for Cell and Gene Therapy?Both community and academic delivery models play essential and complementary roles in expanding CGT access.
Latest:
Bringing Data to Life: How Tech-Savvy Life Sciences Companies Can Better Serve the Healthcare SectorGoing beyond traditional market segmentation to understand the technological and data analytics capacity of target customers.
Latest:
Mastering Your AI Budget for 2025 SuccessBecause the AI space is changing rapidly, it’s essential that companies are budgeting correctly and using their investments strategically.
Latest:
Pharma Forecasting: Key Markets Investors Can’t IgnoreThe importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.
Latest:
AI to Impact Clinical Trials and Manufacturing in Life SciencesArtificial intelligence may find a home in clinical trials and manufacturing in the coming years, but privacy, cyber security, and determining who owns the intellectual properties could pose challenges.
Latest:
Filling the Void in Pharmacy Student TrainingPreceptor and mentorship opportunities now more important than ever.
Latest:
Embracing Programmatic Advertising to Enhance Targeting of HCPsThe precision of programmatic advertising is reshaping the way life sciences brands engage with healthcare professionals, offering enhanced personalization, scale, and optimization in today's digital landscape.
Latest:
Beyond the Data: Is Blockchain the Answer to Improving Global Health?The COVID-19 pandemic has shifted the adoption of digital platforms in pharma and has made the industry reconsider which technologies can improve global health moving forward.
Latest:
Using ML, AI and RWD to Infer HCP SpecialtiesPharmaceutical sales operations teams often rely on outdated or inaccurate data when prioritizing HCP targets, limiting promotional effectiveness. By applying artificial intelligence and machine learning to real world data, pharmaceutical companies can more effectively target physicians hiding in plain sight and PCPs behaving like specialists.
Latest:
The Potential of ProteomicsMajor stakeholders—including policymakers, public-private interests, and academia—are increasingly embracing the potential of proteomics technology in reshaping diagnostics and patient care.
Latest:
The Polymath: A New Commercial Role in the Pharma IndustryPharma requires leaders who are "polymaths" — that is, those with the breadth and depth of experience within each of the sub-functions of commercial operations. Niti Sawhney reports.
Latest:
The Complexities of Drug DiscountingHow fragmented savings undermine transparency, patient savings, and the pharma ecosystem.
Latest:
In DOJ Crosshairs: Rethinking Commission-Based Deals With Independent ContractorsPharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.
Latest:
Exploring the Advantages of Innovative Early Phase Trial DesignIn early phase trials innovative designs offer potential for improvements in efficiency and decision-making.
Latest:
CMS Signals Looming Sunshine Act Audits: How to PrepareNew guidance suggests that CMS may be ramping up Sunshine Act auditing activities, potentially resulting in monetary liability for noncompliant reporting entities.
Latest:
Manage Risk Effectively to Improve the Value of Your AllianceIn this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
